Immunotherapy drug tested for mysterious cancers

NCT ID NCT05024968

Completed Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tested the drug sintilimab in 10 people with advanced cancer of unknown primary (CUP), a rare cancer where doctors cannot find where it started. Participants received sintilimab every 3 weeks for up to 24 months. The study measured how many patients' tumors shrank or disappeared and tracked side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sintilimab (an immunotherapy drug given by IV)
What this could lead to: If it works, this could point toward a new treatment option for people with cancer of unknown primary who have run out of standard options.
What could go wrong: This is a very small, early-phase trial with only 10 participants, so results may not apply broadly. Immunotherapy can cause side effects like inflammation in healthy organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER OF UNKNOWN PRIMARY SITE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer of unknown primary site Neoplasms, Unknown Primary

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER OF UNKNOWN PRIMARY SITE

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.